CONDITION
Dilated Cardiomyopathy in Dogs
Dilated cardiomyopathy is a condition in which the heart muscle becomes progressively weaker and the main pumping chambers enlarge. As the walls of the heart stretch and thin, the muscle loses its ability to contract forcefully, and blood begins to move less efficiently through the circulation. Over time, this can lead to fluid accumulating in the lungs or abdomen, and to episodes of collapse or sudden death from rhythm disturbances. Owners often arrive at this page because their dog has started coughing, breathing more rapidly at rest, tiring unusually quickly on walks, or has had an episode of weakness or collapse. Some dogs are investigated after a murmur or irregular heartbeat is heard during routine examination, before any outward signs appear. In certain breeds—including Dobermanns, Irish Wolfhounds, and Great Danes—the condition can progress silently for months or years. This page explores what may be observed at different stages, the mechanisms that drive the disease, how it is investigated using imaging and rhythm monitoring, and the medical approaches used to manage fluid overload, support heart function, and address arrhythmias. It does not diagnose an individual animal, but offers a framework for understanding what dilated cardiomyopathy is and how it tends to unfold.
Why this matters now
Dilated cardiomyopathy tends to appear in middle-aged to older dogs, typically between four and ten years of age, though younger animals can occasionally be affected. Certain breeds show a higher incidence, including large and giant breeds such as Dobermann Pinschers, Irish Wolfhounds, and Great Danes, as well as medium-sized breeds such as Cocker Spaniels, which are particularly associated with a taurine-deficiency-related form of the condition. In some breeds, specific genetic mutations have been identified, while in others the underlying cause remains uncertain. Nutritional factors, particularly taurine or carnitine deficiency, have been associated with the condition in certain breeds and diets, though the relationship is complex and not fully understood.
The condition often develops quietly over months to years, with the heart gradually enlarging and weakening before outward signs become apparent. Some dogs may move from early changes detectable only on imaging to advanced heart failure over weeks to months, while others may remain stable for extended periods. The rate of progression varies considerably between individuals, influenced by factors including breed, the extent of underlying muscle damage, and the presence of rhythm disturbances. Once signs of fluid accumulation or reduced exercise tolerance emerge, the trajectory often accelerates, though the timeframe remains unpredictable for any individual animal.
Signals & patterns
Early signals
Reduced stamina during walks
A dog may tire more easily on familiar routes or show less enthusiasm for activities they previously enjoyed. This change can be subtle and gradual, easily mistaken for normal ageing or hot weather.
Occasional coughing
A soft, intermittent cough may appear, particularly after rest or at night. The pattern can resemble a throat irritation rather than an obvious respiratory problem, and may not occur daily.
Faster breathing at rest
The breathing rate when settled or asleep may increase slightly, often noticed by owners who routinely observe their dog's sleeping patterns. The change may be as subtle as ten to fifteen breaths per minute above the previous baseline.
Restlessness at night
A dog may wake more frequently, shift position often, or struggle to settle comfortably. This behaviour can reflect subtle difficulty breathing when lying flat, though many other factors can also cause disturbed sleep.
Later signals
Laboured breathing
Breathing becomes visibly effortful, often rapid and shallow, with the chest and abdomen moving more obviously than usual. The pattern may worsen when lying down, prompting the dog to sit or stand instead.
Collapse or weakness
Episodes of sudden weakness or collapse may occur, sometimes lasting only seconds. These events can reflect rhythm disturbances or insufficient blood flow to the brain and muscles, though other conditions can produce similar patterns.
Abdominal swelling
The abdomen may appear distended or feel firm, reflecting fluid accumulation in the belly cavity. This change tends to develop gradually and may be accompanied by reduced appetite or reluctance to lie down fully.
Click to read about the biological mechanisms
How this is usually investigated
Investigation of suspected dilated cardiomyopathy typically begins with a careful history and physical examination, during which subtle changes such as a heart murmur, gallop rhythm, arrhythmia, or muffled heart sounds may be detected. When clinical signs are present or when screening at-risk breeds, the investigation progresses to tests that characterise cardiac structure, function, and rhythm. The combination of investigations used depends on the clinical picture, the breed, and whether the goal is diagnosis of overt disease or detection of occult (preclinical) changes.
Physical examination
Echocardiography
Radiography
24-hour Holter monitoring
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Options & trade-offs
Management of dilated cardiomyopathy is typically multimodal, combining medications that address the consequences of reduced cardiac output and neurohormonal activation with adjustments to diet and activity. The combination chosen depends on the stage of disease (occult versus overt heart failure), the individual dog's response, and practical considerations for the household. What works well for one dog and owner may be less suitable for another, and approaches often evolve as the condition progresses.
ACE inhibitors and aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors such as enalapril or benazepril, and aldosterone antagonists such as spironolactone, act on the renin-angiotensin-aldosterone system to reduce sodium and water retention, decrease afterload (the resistance the heart pumps against), and mitigate some of the harmful effects of chronic neurohormonal activation on the myocardium. These medications are often introduced when systolic dysfunction is identified, even before overt heart failure develops, and continued long-term.
Trade-offs: These drugs require monitoring of renal function and electrolytes, as they can affect kidney perfusion and potassium balance, particularly when used in combination or in dogs with concurrent renal disease. The benefit in the occult phase is debated for some breeds, and dose adjustments may be needed over time.
Positive inotropes
Pimobendan is a positive inotrope (it increases the strength of myocardial contraction) and vasodilator, widely used in dogs with DCM once echocardiographic evidence of systolic dysfunction is present. In Dobermann Pinschers with preclinical DCM, pimobendan has been shown to delay the onset of overt heart failure and extend survival, and it is commonly used in overt heart failure across breeds to improve cardiac output and clinical signs.
Trade-offs: Pimobendan is generally well tolerated, though it increases myocardial oxygen demand and in rare cases may exacerbate arrhythmias. Its benefit in occult DCM in breeds other than Dobermanns is less well established, and the decision to start treatment in the absence of clinical signs involves weighing potential benefit against cost and the commitment to long-term medication.
Diuretics
Furosemide (frusemide) is the diuretic most commonly used to manage pulmonary oedema and effusions in dogs with congestive heart failure, promoting the elimination of excess fluid and relieving respiratory distress. The dose is adjusted according to the severity of congestion and the dog's response, and in many cases chronic low-dose therapy is continued after the initial crisis is controlled.
Trade-offs: Diuretics can cause dehydration, electrolyte disturbances (particularly low potassium), and prerenal azotaemia, and they require careful dose titration and periodic monitoring of renal function and hydration status. Over-diuresis can reduce cardiac output by decreasing preload excessively, whilst under-treatment leaves the dog uncomfortable and at risk of worsening congestion.
Antiarrhythmic therapy
When ventricular arrhythmias are frequent, complex, or associated with clinical signs such as weakness or collapse, antiarrhythmic drugs may be introduced. Options include sotalol, mexiletine, or amiodarone, chosen based on the characteristics of the arrhythmia and the individual dog's tolerance. The goal is to reduce arrhythmia burden and the risk of sudden death, though complete suppression is often not achievable.
Trade-offs: Antiarrhythmic drugs can themselves be proarrhythmic (capable of worsening or inducing new arrhythmias), and they often require monitoring with repeat Holter studies or electrocardiograms to assess efficacy and detect adverse effects. Response is variable, and in some dogs arrhythmias persist despite treatment.
Dietary modification and taurine or carnitine supplementation
In dogs with DCM, particularly those on grain-free or legume-rich diets or certain breeds with historical associations between diet and DCM (such as Cocker Spaniels), dietary modification and supplementation with taurine and/or L-carnitine is sometimes pursued. The rationale is that deficiencies in these nutrients can contribute to myocardial dysfunction in some cases, and supplementation may stabilise or, rarely, partially reverse cardiac changes if a nutritional component is present.
Trade-offs: The role of diet and supplementation remains unclear in many cases, and response is unpredictable; some dogs show echocardiographic improvement whilst others do not, and it is often impossible to know whether supplementation has altered the disease course. Dietary change can be practically difficult in dogs with established preferences, and the evidence base for supplementation in genetically driven DCM is limited.
Common misconceptions
"A heart murmur is always the first sign of dilated cardiomyopathy."
Many dogs with DCM, particularly in the early (occult) phase, have no murmur at all, and the condition may only be detected through echocardiography or Holter monitoring during screening. Murmurs, when present, typically arise from mitral regurgitation secondary to ventricular dilation rather than being a primary feature of the disease, and some dogs develop overt heart failure without ever having a prominent murmur.
"Dilated cardiomyopathy can be cured if detected early enough."
DCM is a progressive and irreversible disease; the myocardial damage and fibrosis that characterise the condition cannot be undone. Treatment aims to slow progression, manage the consequences of reduced cardiac function, and improve quality of life, but it does not restore normal cardiac structure or function. Even with treatment, the disease typically advances over time, though the rate of progression varies considerably between individuals.
"All large-breed dogs are equally at risk of dilated cardiomyopathy."
Whilst DCM predominantly affects large and giant breeds, the risk is far from uniform; certain breeds such as Dobermann Pinschers, Great Danes, and Irish Wolfhounds have well-documented genetic predispositions and much higher prevalence than other large breeds. Breed-specific genetic mutations underlie familial DCM, and dogs of non-predisposed breeds, even if large, are at considerably lower baseline risk unless other factors (such as specific dietary exposures) are present.
Related conditions
Hypertrophic Cardiomyopathy in Cats
Hypertrophic cardiomyopathy in cats represents a different structural heart disease—thickening rather than dilation—but shares similar consequences including impaired cardiac output and the potential for circulatory complications. Understanding both conditions can help owners recognise that heart muscle disease takes different forms across species.
Hypothyroidism in Dogs
Hypothyroidism in dogs has historically been considered a possible contributor to dilated cardiomyopathy in some cases, though current evidence suggests this link may be less common than once thought. Thyroid hormone influences cardiac muscle metabolism, and severe or prolonged deficiency can occasionally affect heart function.
Pericardial Effusion
Pericardial effusion can occur as a complication in some dogs with dilated cardiomyopathy, particularly when heart failure leads to fluid accumulation around the heart. Both conditions may present with similar signs of reduced exercise tolerance and circulatory compromise, though their underlying mechanisms differ.
Obesity in Dogs
Obesity in dogs increases metabolic demand on the cardiovascular system and may influence the progression or clinical expression of dilated cardiomyopathy in affected individuals. Weight management can be part of the broader supportive context when heart function is already compromised.
Laryngeal Paralysis in Dogs
Laryngeal paralysis and dilated cardiomyopathy may both occur in older large-breed dogs, and in some cases appear to be part of a broader syndrome of nerve and muscle dysfunction. Owners may observe breathing difficulty in either condition, though the anatomical origin differs.
For owners of predisposed breeds, understanding the rationale and timing of cardiac screening — echocardiography and Holter monitoring — can be a useful conversation to have, particularly as the dog approaches middle age. In dogs with a confirmed diagnosis, attention often extends to recognising the early signs of decompensation (such as changes in breathing pattern, exercise tolerance, or appetite) and understanding how the management plan may evolve as the condition progresses. The broader context of cardiovascular health, the interplay between cardiac and renal function, and the role of nutrition and body condition in chronic disease may also be relevant as part of the wider picture of longevity and healthspan.
Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS